We
have acted as special tax counsel to
JPMorgan Chase & Co., a corporation incorporated under the laws of Delaware
(the “Company”), in connection with the preparation and filing of pricing
supplement no. 532 dated July 3, 2007 relating to Principal Protected Notes
Linked to a Weighted Basket Consisting of the Russell 3000
®
Index,
the Dow Jones
EURO STOXX 50
®
Index and the Nikkei 225 Index due July 7, 2011 (the “Pricing Supplement”) to
product supplement no. 32-VII dated June 29, 2007 relating to Principal
Protected Notes Linked to a Weighted Basket Consisting of the AMEX Hong Kong
30
Index, the Dow Jones EURO STOXX 50
®
Index,
the FTSE
TM
100 Index,
the
FTSE/Xinhua China 25 Index, the Korea Stock Price Index 200, the MSCI EAFE
®
Index,
the
iShares
®
MSCI
Emerging Markets Index Fund, the MSCI Taiwan Index, the MSCI Singapore
Index,
the
Nikkei 225 Index, the Russell 2000
®
Index,
the Russell
3000
®
Index
and
the S&P 500
®
Index, or Linked to Any One of the Foregoing (the “Product Supplement”) to a
prospectus supplement dated October 12, 2006 (the “Prospectus Supplement”) for
the Company’s Global Medium-Term Notes, Series E, Global Warrants, Series E and
Global Units, Series E, relating to a prospectus dated December 1, 2005 (the
“Prospectus”) contained in the Company’s Registration Statement on Form S-3ASR
(Registration Statement No. 333-130051) (the “Registration
Statement”). This opinion is being furnished in accordance with the
requirements of Section 601(b)(8) of Regulation S-K of the Securities Act
of
1933, as amended (the “Act”).
In
our opinion, the discussions under
the heading “United States Federal Taxation” in the Prospectus Supplement, under
the heading “Certain U.S. Federal Income Tax Consequences” in the Product
Supplement and under the heading “Selected Purchase Considerations –
Taxed as Contingent Payment
Debt
Instruments” in the Pricing Supplement
, subject to the conditions and
limitations described therein, set forth the material U.S. federal income
tax
considerations applicable generally to holders of the securities offered
pursuant to the Pricing Supplement as a result of the ownership and disposition
of such securities.
We
hereby consent to the filing of this
opinion as an exhibit to the Registration Statement and to the references
to us
under the heading “United States Federal Taxation” in the Prospectus Supplement,
under the heading “Certain U.S. Federal Income Tax Consequences” in the Product
Supplement and under the heading “Selected Purchase Considerations –
Taxed as Contingent Payment
Debt
Instruments” in the Pricing Supplement
. By such consent we do
not concede that we are an “expert” for the purposes of the
Act.